Abstract. Cardiac transplantation is now an accepted therapeutic option for patients with end-stage myocardial failure. Provided donor and recipient are appropriately selected and adequately matched, expected survival rates at one and five years are 85°7o and 65o7o, respectively. Two major challenges are encountered in clinical heart transplantation. The first is monitoring immunosuppression for adequate prevention of acute rejection and surveillance for side effects. The endomyocardial biopsy remains the gold standard for rejection surveillance, but since it is an invasive procedure which can only be performed at arbitrary time intervals, the search for non-invasive methods continues. The approach to immunosuppression currently practised by most centers is that of combination drug therapy, which allows low doses with decreased potential for side effects. At Stanford, immunosuppression is usually initiated with OKT3, corticosteroids, and cyclosporine, and maintained with a combination of steroids, cyclosporine, and azathioprine. The most frequently encountered complications include bacterial and opportunistic infections, cyclosporine nephrotoxicity, and malignancy. The second challenge is accelerated coronary disease, which has emerged as the major factor limiting long-term survival. It is usually clinically silent and often presents with sudden death, acute myocardial infarction, or progressive unexplained graft failure. Coronary arteriography is currently the only method for premorbid diagnosis, and retransplantation the only effective therapy.
heart transplantation. Initial enthusiasm was soon quelled by the complexities of postoperative management and associated high mortality, which forced many centers to abandon the procedure. At Stanford, research in immunosuppression and infectious disease, with careful monitoring of patients, led to progressive improvement in survival rates. Currently, provided donor and recipient are appropriately selected and adequately matched, expected survival rates at one and five years are 85% and 65o/0, respectively [2] . This improved survival over the past two decades ( Fig. 1) has contributed to the increasing number of transplants performed each year world-wide [2] .
Despite considerable experience in pre-and postoperative aspects of cardiac transplantation, clinical management of these patients contiues to challenge physicians. Major advances in immunosuppression have only partially improved the specificity of agents which prevent and treat rejection. The potential for complications from such broad-based immunosuppressive regimens dictates the major objectives in management of cardiac transplant recipients. These objectives include: rigorous surveillance for adequacy of immunosuppression to prevent and treat acute allograft rejection; early detection of accelerated coronary disease, which is thought to represent chronic rejection; and monitoring for complications of immunosuppression such as infection, malignancy, nephrotoxicity, hepatotoxicity, and drug interactions. This article reviews the current status of clinical cardiac transplantation, with particular emphasis on longterm management, and outlines some major challenges for its further improvement.
Indications for cardiac transplantation
The goal of cardiac transplantation is to return persons who would otherwise die, or be severely disabled by end-stage heart failure, to a functional life style. Appropriate selection of patients is essential for achieving this goal and for optimal use of the scarce supply of donor hearts. Over the past 20 years of experience in heart transplantation we have evolved criteria for optimal selection of recipients (Table 1) .
In considering transplantation for severe myocardial failure, the physician should first determine whether a more conventional therapy is likely to benefit the patient. All attempts should be made to explore even high risk surgical procedures, with careful consideration of their associated mortality. In many patients with severely depressed ventricular function secondary to coronary artery or vascular disease, conventional management of the underlying cause may result in amelioration of symptoms and partial recovery of functional capacity. For example, intractable angina In contrast, patients with severe mitral regurgitation due to a dilated mitral annulus without organic mitral valvular disease rarely achieve any functional improvement with mitral valve replacement. Ventricular arrhythmia is frequently the predominant clinical problem in patients with severe myocardial dysfunction as a consequence of coronary disease. Such patients should be initially managed by aggressive pharmacologic therapy directed by electrophysiologic testing; and implanation of an automatic defibrillator should be considered before resorting to cardiac transplantation. Rare causes of potentially treatable myocardial disease, such as sarcoidosis or myocarditis, should be excluded by endomyocardial biopsy. These conditions may respond to steroid therapy sufficiently to postpone or preclude transplantation [3] .
Contraindications to cardiac transplantation
One of the major medical contraindications to transplantation is irreversible pulmonary vascular disease (Table 1) . This complication poses a considerable risk for acute right heart failure and graft loss immediately post-transplantation. It is therefore essential to establish in all potential recipients that pulmonary hypertension is primarily due to left heart failure, and is reversible by afterload reducing agents such as sodium nitroprusside. Although systemic diseases are regarded as contraindications to cardiac transplantation, patients in certain categories may be acceptable candidates. For example, patients with maturity-onset, noninsulin-dependent diabetes may be accepted, provided no end-organ damage is present. Likewise, patients with a history of lymphoproliferative disorders thought to be cured may be accepted following rigorous oncologic evaluation.
Maintenance immunosuppression
Maintenance immunosuppression has steadily improved during the past 20 years. Prior to 1980, patients were treated with a high dose intravenous triple therapy of prednisone, azathioprine and anti-thymocyte globulin (ATG). ATG was discontinued after the third or fourth week, and corticosteroid doses were tapered from an initial 1.5mg/kg/day to a minimum of 0.25 mg/kg/day [4] . Azathioprine was continued at the highest dose compatible with peripheral white cell blood count >4.0~t/dl. From 1980 to 1983 cyclosporine replaced azathioprine [5] . Cyclosporinebased immunosuppression was associated with mark-ed improvement in survival, as a consequence of decreased mortality from infectious complications [6] . Unfortunately, the nephrotoxicity of cyclosporine soon became apparent, requiring the reintroduction of azathioprine in 1983 to allow lower doses of cyclosporine to be used [7] .
In 1985 prophylactic use of ATG at Stanford was discontinued due to lack of its availability. The ensuing increase in early rejection episodes (unpublished data) prompted introduction of the OKT3 monoclonal antibody for prophylaxis during the first two weeks following transplantation. Initial experience with monoclonal OKT3 was in renal transplantation, where clinical trials demonstrated effective rejection prophylaxis [8] . Subsequently, similar results were reported in heart transplant recipients [9] [10] [11] , and superior prophylaxis was noted compared to conventional agents such as steroids and ATG.
OKT3 has two major effects. First, there is an immediate decline in circulating T-cells, caused by coating of the cell surface with the antibody and subsequent removal by the reticuloendothelial system. This effect is probably similar to that of ATG. Second, there is direct interference with the antigen recognition apparatus produced by binding the antibody with the CD3 cell surface antigen. This process renders T-cells incapable of interacting with foreign antigens and produces rapid inhibition of T-cell function.
The effect of OKT3 on antigen recognition modulation at a proximal point in the rejection pathway is distinct from that of other immunosuppressive agents. OKT3 has altered the pattern of acute rejection by reducing early rejection incidence [11] . Currently, many patients experience their first rejection episode four or five weeks post-transplantation. As a major potential long-term advantage, OKT3 may allow lower doses of conventional immunosuppressive drugs to be used, lessening the complications of steroid therapy and cyclosporine nephrotoxicity.
Monitoring for acute rejection
The development of percutaneous transvenous endomyocardial biopsy techniques by Caves and Schultz [12] and the definition of histologic criteria for diagnosis of acute rejection by Billingham [13] were major milestones in cardiac transplantation. The endomyocardial biopsy allows surveillance, which avoids unnecessary augmentation of immunosuppression. Before the introduction of cyclosporine, clinical signs of ventricular dysfunction, such as a third heart sound or a decrease in summated electrocardiographic voltage, were sufficiently sensitive for monitoring rejection [4] . Biopsies were performed only to confirm the presence of acute rejection before beginning therapy. Since rejection in patients treated with cyclosporine is characteristically clinically silent, endomyocardial biopsies have to be performed routinely and graded histologically according to the Billingham criteria: no rejection; mild: cellular infiltrate only; moderate: cellular infiltrate with myocyte necrosis; severe: hemorrhage in addition to cellular infiltration and myocyte necrosis.
Histologic grading is crucial in making therapeutic decisions. In the absence of myocyte necrosis many centers, including Stanford, do not augment immunosuppression. Conversely, severe rejection may prompt more aggressive therapies and more frequent follow-up biopsies. Currently, biopsies are routinely performed on a weekly basis during the initial four weeks, every two weeks during the subsequent six weeks, and every four to six weeks after the third postoperative month. Since rejection incidence declines progressively with time, routine endomyocardial biopsies after the first year are obtained every three or four months. Occasionally these biopsies reveal moderate acute rejection which may have begun at any time after the previous biopsy. Thus, a noninvasive method of screening would enable early diagnosis and reduce the number of biopsies.
Doppler echocardiographic assessment of diastolic function has been proposed for noninvasive monitoring of rejection [14] . Development of a restrictive pattern of left ventricular filling associated with rejection may be recognized from the mitral flow velocity curve recorded by pulsed wave Doppler ultrasound. The sensitivity of Doppler indices of diastolic function for predicting acute rejection is being evaluated in a prospective blinded study. Other noninvasive surveillance methods currently being investigated include nuclear magnetic resonance spectroscopy [15] and cytoimmunological monitoring [16] .
Treatment of acute rejection
The decision to treat acute rejection in the intermediate and late periods post-transplantation is based primarily on endomyocardial biopsy findings, but is also influenced by the clinical features of each case. In patients with overt signs of myocardial dysfunction, augmentation of immunosuppression is frequently instituted before the results of endomyocardial biopsy are available. Conversely, the presence of an inflammatory infiltrate without myocyte necrosis on a routine biopsy is an indication for earlier repeat biopsy to assess progression to moderate rejection. This strategy is based on our experience that 50°70 of biopsies showing a cellular infiltrate without myocyte necrosis clear spontaneously.
The treatment for acute rejection depends on the patient's rejection history, prior immunosuppression, and severity of rejection histologically and hemodynamically. The first three biopsies showing moderate acute rejection are usually treated with high dose corticosteroids, either intravenous methylprednisolone 1 g on three consecutive days, or oral prednisone 100 mg daily with rapid tapering down of the dose. Failure to respond to corticosteroid therapy is an indication for anti-thymocyte globulin or OKT3 monoclonal antibody. Recent reports have shown that OKT3 is highly effective in reversing cardiac allograft rejection refractory to conventional therapy. However, since OKT3 is a routine protein, it can stimulate production of anti-idiotypic antibody, which may hinder its efficacy for repeated use.
Production of this antibody may be monitored by measuring the percentage of T-lymphocytes expressing the CD3 + marker. If this percentage is not less than 1°70, it is presumed to indicate the presence of an antiidiotypic antibody. Occasionally patients continue to show biopsy evidence of acute rejection despite these therapeutic interventions. In the presence of significant ventricular dysfunction, retransplantation may be considered. However, the results of retransplantation are inferior to those for the first transplant [17] . Mortality is frequently related to continued severe rejection in the retransplanted graft, or to infection. Total lymph node irradiation is currently being investigated for refractory rejection, and should be considered as a therapeutic option before transplantation.
Monitoring of immunosuppressive drugs
Three drugs, prednisone, cyclosporine, and azathioprine, provide the mainstay of maintenance immunosuppression. Current evidence indicates that optimal maintenance immunosuppression is achieved by using a combination of all three, thus permitting their use in low doses and decreasing the propensity for side effects. Nonetheless, patients still require close surveillance for infection, malignancy, excessive bone marrow suppression, nephrotoxicity, hepatotoxicity, glucose intolerance, and osteoporosis.
Infection
The spectrum of infectious complications in cardiac transplant recipients has not changed significantly with alterations in immunosuppressive regimens. Bacterial infections still account for the majority of infections (Table 2) . At Stanford, though the overall incidence of infectious complications has remained unchanged compared to the pre-cyclosporine era, a marked decrease in associated mortality has been noted (Fig. 2) . Since the majority of infections are pulmonary [4] , surveillance in the intermediate or late postoperative period requires regular chest x-rays. An asymptomatic pulmonary nodule or infiltrate diag- nosed on a routine chest x-ray is frequently the first sign of infection. These lesions should be investigated promptly by bronchoscopy or transcutaneous needle aspiration. The most frequently isolated opportunistic organisms are nocardia, aspergillus, and pneumocystis. Nocardia is treated with a prolonged course of gantrisin, and aspergillus requires amphotericin administered to a total dose of 2 g. Careful monitoring of renal function is needed during therapy with both these drugs. Pneumocystis pneumonia frequently presents in the intermediate and late postoperative periods, and its incidence may be increased in patients who receive OKT3 prophylaxis [12] . Its presentation may be very subtle with only minor radiographic abnormalities, minimal dyspnea, and the absence of fever. The most helpful clue is hypoxia, which should prompt early bronchoscopy to obtain specimens for confirmation of the diagnosis. The treatment is initiated with high dose intravenous co-trimoxazole for one week and continued with oral co-trimoxazole for the remaining course of two weeks. Therapy should be started in hospital because of a tendency to worsening hypoxia with initiation of treatment. Close surveillance for side effects of sulfa-and trimethoprim-containing antibiotics requires regular measurement of conventional indices of renal, hepatic and bone marrow function. Cytomegalovirus (CMV) pneumonitis frequently presents during the fourth to sixth postoperative weeks, and the incidence appears to be slightly increased in patients who have been treated with OKT3 [12] . The most common presenting feature is fever, and radiographic changes may be minimal. A rise in liver enzymes is frequently noted, consistent with an associated hepatitis. The diagnosis is confirmed by the presence of typical inclusion bodies on transbronchial biopsies, positive shell vial cultures, and a rise in antibody titers. Preliminary reports have indicated that gancicylovir is highly effective for treatment of CMV infection, and its efficacy for prophylaxis is currently under investigation. Gancicylovir may be obtained for compassionate use in life-threatening CMV infections.
Surveillance for malignancy
Increased incidence of malignancy, particularly the lymphoproliferative type, is a well recognised complication of long-term immunosuppression. Hence, regular assessment of transplant recipients should include careful physical and radiographic examination for lymphadenopathy. Abnormal lymph nodes should be aggressively investigated to obtain a definitive tissue diagnosis. Although not much has been published on treatment of these malignancies, our experience at Stanford indicates that many will regress in response to reduction of immunosuppression.
Monitoring cyclosporine therapy
Cyclosporine, first introduced into clinical cardiac transplantation in 1980 at Stanford, is a lipophilic endecapeptide obained from tolypocladium inflatum gams. Several lessons were learned from the initial experience. The overall result of transplantation with cyclosporine A is improved from 50°70 to at least 85% one year survival. When used with extensive immunosuppressive regimens, there is a high risk of lymphomas [4] . In some patients, cyclosporine A produces excellent protection against rejection; these patients display a much more benign course. Cyclosporine A tends to mask the clinical signs of allograft rejection, increasing dependence on endomyocardial biopsy for diagnosis and assessment of response to therapy [4] .
At Stanford, a number of patients treated with cyclosporine A developed progressive deterioration of renal function which would require renal dialysis unless the trend were reversed [7] . An attempt was made to abrogate nephrotoxicity by discontinuing cyclospofine and substituting azathioprine as the major immunosuppressive agent in patients whose creatinine clearance fell to < 40.0 mls/min and whose serum creatinine increased to > 2.0 mg/dl. Such immunoconversion resulted in improved renal function in 14 of 15 patients. However, cardiac allograft rejection occurred in 8 of 15 patients within three months of stopping cyclosporine, and 5 more developed acute rejection on surveillance right ventricular biopsies during the following nine months. The rejection incidence was considered unacceptably high, and a 50% dose reduction of cyclosporine was instituted. This regimen resulted in renal function improvement comparable to that following complete withdrawal (Fig. 3) , and was associated with less allograft rejection and lower maintenance prednisone requirements. As a result, cyclosporine is now halved in patients developing serum creatinine >2mg/dl, while azathioprine is concurrently increased to white blood cell tolerance. The maintenance prednisone dose is temporarily increased during the initial period of immunoconversion, and endomyocardial biopsies are performed at two-week intervals to ensure that rejection is not precipitated.
In patients receiving cyclosporine, serum creatinine and clearance do not accurately reflect the glomerular filtration rate. The discrepancy is related to renal tubular secretion of creatinine during cyclosporine therapy. However, serial measurements of serum creatinine are sufficiently sensitive to identify any clinically significant change in renal function. For more accurate measurements of glomerular filtration rate, inulin clearance should be employed.
The relationship of structural changes to functional impairment has been examined by means of renal biopsies and inulin clearance [18] . Although characteristic lesions were described, the relationship of structure to function does not appear linear, since progression may occur despite apparent improvement in renal function when cyclosporine is discontinued. Further studies are required to fully define the natural history of cyclosporine nephrotoxicity. Each of the three major causes of decreased glomerular filtration rate has been implicated in cyclosporine nephrotoxicity: increased proximal tubular pressure, decreased filtration coefficient, and vasoconstriction. The initial Stanford experience suggested a direct glomerular toxicity, which would progress to irreversible renal failure [18] . Subsequent results [7] have not supported this hypothesis, but rather indicate reversible renovascular ischemia in the majority of patients, which may predispose to the development of glomerular sclerosis.
The administration of cyclosporine is monitored by measurement of blood levels. The most specific technique for quantification is high performance liquid chromatography (HPLC). The sole advantage of HPLC over other methods is that it estimates parent cyclosporine A distinct from its metabolites. HPLC is laborious and requires complex instrumentation and lengthy analysis time. For these reasons, most centers There is considerable controversy regarding the appropriate matrix (whole blood or plasma) for determining cyclosporine concentrations. Eighty percent of cyclosporine is bound to erythrocytes, and its distribution between plasma and blood cells is temperature-dependent. The manufacturers of RIA kits have recommended therapeutic ranges for whole blood and serum concentrations of cyclosporine. The recommended therapeutic window for trough serum concentrations measured by RIA after 60 days of therapy is 75 -150 ng/ml, and for whole blood 200 to 600 ng/ml; however, the optimal concentration differs among patients due to variable individual cyclosporine pharamcodynamics, simultaneous drug effects on metabolism, toxicity, and idiosyncratic reactions. Currently, because of its nephrotoxicity, the trend is toward a lower dose of cyclosporine used with azathoprine and prednisone. Further progress will depend on results of controlled trials to identify the optimal combination of immunosuppressive agents that achieves synergistic activity with low toxicity.
Monitoring for accelerated coronary artery disease
Accelerated graft atherosclerosis is a major complication affecting long-term survival of heart transplant patients. Since the cardiac allograft remains denerrated, angina does not occur, and silent myocardial infarction or sudden death is frequently the first sign of transplant coronary artery disease. Noninvasive tests of myocardial ischemia have been uniformly insensitive for diagnosing this complication [19] , and serial coronary arteriograms are essential. The time-related prevalence of coronary artery disease in patients surviving at least one year after transplantation at Stanford, 15°70 to 50070, is unaltered by cyclosporine immunosuppression. As survival increases with decreased mortality from infection, transplant coronary artery disease has become a major clinical problem. The etiology of accelerated graft atherosclerosis is unknown, although some reports have suggested a relationship to rejection incidence, fasting plasma triglyceride levels, and donor age [20] . Coronary artery disease may occur as early as six months post transplantation, and may be under-estimated by a single coronary arteriogram. Owing to the diffuse nature of this disease, side-by-side comparison of annual coronary arteriograms is required for careful assessment of this complication.
The histopathologic changes found in patients with transplant coronary artery disease consist of intimal proliferative lesions and atherosclerotic plaques [21] . The latter are similar in histologic composition and distribution to those in non-transplant coronary disease. In contrast, the intimal proliferation of transplant coronary artery disease tends to affect vessels throughout their length, and diffuse endothelial cell proliferation occurs with fibro-obliterative lesions causing narrowing or total occlusion. Complementfixing immunoglobulins have been recognized in these lesions, suggesting immune mediated injury, perhaps aggravated by an atherogenic environment. Multiple prophylactic regimens, including warfarin, dipyridamole, and aspirin, have been unsuccessful in influencing the incidence of transplant CAD [20] . Currently, patients at Stanford still receive antiplatelet prophylaxis, and att~apts are made to control serum cholesterol levels by dietary measures.
Treatment of severe coronary disease is difficult because of its anatomical characteristics, which preclude bypass surgery or balloon angioplasty. Absence of collateral vessels and the diffuse distribution may contribute to the lethal nature of this disease. As yet the only effective approach to treatment of severe transplant coronary disease is retransplantation. The one-year survival rate of 55 % after retransplantation, with current survival extending to five years, shows that this approach can be successful. The indications for optimal timing of retransplantation have yet to be fully defined, since occasionally patients survive many years, despite severe coronary artery disease of their graft.
Summary
As more centers embark on cardiac transplantation and survival rates improve, greater numbers of physicians will be involved in the long-term management of these patients. The major emphasis of care is directed toward complications of immunosuppressive therapy, monitoring for rejection, and surveillance for accelerated coronary disease. The management of heart transplant patients, therefore, provides great challenges not only for the cardiologist but also for the internist, with a wide range of subspecialty interest.
